Skip to main content

Advertisement

SpringerLink
Log in

HIV and coinfected patients

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) infections are major public health problems. Patients at risk for HIV infection are likely also at risk for HCV and HBV because of shared routes of transmission. HIV and antiretroviral therapy (ART) have a significant impact on HCV and HBV. HIV coinfection accelerates HCV and HBV natural history, leading to an increased incidence of cirrhosis, development of hepatocellular carcinoma (HCC), and death. Universal screening for HCV and HBV infections in HIV-infected patients is essential. Proper screening combined with up-to-date treatment strategies can prevent these complications. This review focuses on important aspects and recent developments in the rapidly evolving field of coinfection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Weber R, Sabin CA, Friis-Moller N, et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632–1641.

    Article  PubMed  Google Scholar 

  2. Danta M, Dusheiko GM: Acute HCV in HIV-positive individuals—a review. Curr Pharm Des 2008, 14:1690–1697.

    Article  PubMed  CAS  Google Scholar 

  3. Bonnard P, Lescure FX, Amiel C, et al.: Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007, 14:806–811.

    Article  PubMed  CAS  Google Scholar 

  4. Sulkowski MS, Mehta SH, Torbenson MS, et al.: Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007, 21:2209–2216.

    Article  PubMed  Google Scholar 

  5. Bani-Sadr F, Lapidus N, Bedossa P, et al.: Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008, 46:768–774.

    Article  PubMed  CAS  Google Scholar 

  6. Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc group. Hepatology 1999, 30:1054–1058.

    Article  PubMed  CAS  Google Scholar 

  7. Mohsen AH, Easterbrook PJ, Taylor C, et al.: Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003, 52:1035–1040.

    Article  PubMed  CAS  Google Scholar 

  8. Martin-Carbonero L, Benhamou Y, Puoti M, et al.: Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: A european collaborative study. Clin Infect Dis 2004, 38:128–133.

    Article  PubMed  Google Scholar 

  9. Brau N, Salvatore M, Rios-Bedoya CF, et al.: Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006, 44:47–55.

    Article  PubMed  CAS  Google Scholar 

  10. Brau N, Fox RK, Xiao P, et al.: Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a US-Canadian multicenter study. J Hepatol 2007, 47:527–537.

    Article  PubMed  Google Scholar 

  11. Puoti M, Bruno R, Soriano V, et al.: Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. AIDS 2004, 18:2285–2293.

    Article  PubMed  Google Scholar 

  12. Clifford GM, Rickenbach M, Polesel J, et al.: Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008, 22:2135–2141.

    Article  PubMed  CAS  Google Scholar 

  13. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al.: Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004, 18:2163–2170.

    Article  PubMed  Google Scholar 

  14. Tural C, Fuster D, Tor J, et al.: Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003, 10:118–125.

    Article  PubMed  CAS  Google Scholar 

  15. Verma S, Wang CH, Govindarajan S, et al.: Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006, 42:262–270.

    Article  PubMed  CAS  Google Scholar 

  16. Macias J, Castellano V, Merchante N, et al.: Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine. AIDS 2004, 18:767–774.

    Article  PubMed  CAS  Google Scholar 

  17. Qurishi N, Kreuzberg C, Lüchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708–1713.

    Article  PubMed  CAS  Google Scholar 

  18. Mocroft A, Soriano V, Rockstroh J, et al.: Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005, 19:2117–2125.

    Article  PubMed  Google Scholar 

  19. Nunez M, Soriano V: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005, 28:53–66.

    Article  PubMed  CAS  Google Scholar 

  20. Labarga P, Soriano V, Vispo ME, et al.: Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196:670–676.

    Article  PubMed  CAS  Google Scholar 

  21. Thein HH, Yi Q, Dore GJ, et al.: Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22:1979–1991.

    Article  PubMed  Google Scholar 

  22. Soriano V, Puoti M, Sulkowski M, et al.: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 2007, 21:1073–1089.

    Article  PubMed  Google Scholar 

  23. Macias J, Recio E, Vispo E, et al.: Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol 2008, 49:916–922.

    Article  PubMed  Google Scholar 

  24. Dore GJ, Torriani FJ, Rodriguez-Torres M, et al.: Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007, 21:1555–1559.

    Article  PubMed  Google Scholar 

  25. Opravil M, Sasadeusz J, Cooper DA, et al.: Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008, 47:36–49.

    Article  PubMed  CAS  Google Scholar 

  26. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and HIV Medicine Association of the Infectious Diseases Society of America (HIVMA/IDSA): Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Available at http://www.aidsinfo.nih.gov/contentfiles/Adult_OI.pdf. Accessed June 2008.

  27. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438–450.

    Article  PubMed  CAS  Google Scholar 

  28. Chung RT, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451–459.

    Article  PubMed  CAS  Google Scholar 

  29. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839–2848.

    Article  PubMed  CAS  Google Scholar 

  30. Laguno M, Murillas J, Blanco JL, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004, 18:F27–F36.

    Article  PubMed  CAS  Google Scholar 

  31. Vispo E, Barreiro P, Rodriguez-Novoa S, et al.: Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antivir Ther 2008, 13:511–517.

    PubMed  CAS  Google Scholar 

  32. Nunez M, Miralles C, Berdun MA, et al.: Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses 2007, 23:972–982.

    Article  PubMed  CAS  Google Scholar 

  33. Mira JA, Lopez-Cortes LF, Barreiro P, et al.: Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008, 62:1365–1373.

    Article  PubMed  CAS  Google Scholar 

  34. Gonzalez-Garcia JJ, Berenguer J, Condes E, et al.: the GESIDA 50/06 Study Group: The use of TDF+ 3TC/FTC is associated with an improved response to pegylated interferon + ribavirin in HIV/HCV-co-infected patients receiving HAART: the GESIDA 50/06 study [abstract 1076]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston; February 3–6, 2008.

  35. Vispo E, Barreiro P, Pineda JA, et al.: Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, 13:429–437.

    PubMed  CAS  Google Scholar 

  36. Pineda JA, Mira JA, Gil Ide L, et al.: Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007, 60:1347–1354.

    Article  PubMed  CAS  Google Scholar 

  37. Moreno A, Quereda C, Muriel A, et al.: Does the choice of NRTI have a significant influence on the outcome of peg-IFN plus ribavirin among HIV-HCV co-infected patients? [abstract 1075]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston; February 3–6, 2008.

  38. Payan C, Pivert A, Morand P, et al.: Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut 2007, 56:1111–1116.

    Article  PubMed  CAS  Google Scholar 

  39. Rodriguez-Torres M, Rockstroh J, Depamphilis J, et al.: On-treatment responses at weeks 4 and 12 can be used to predict sustained virological response rates in HCV/HIV-co-infected patients treated with peg-interferon beta-2a and ribavirin [abstract 1073]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008). Boston; February 3–6, 2008.

  40. Shea DO, Tuite H, Farrell G, et al.: Role of rapid virological response in prediction of sustained virological response to peg-IFN plus ribavirin in HCV / HIV co-infected individuals. J Viral Hepat 2008, 15:482–489.

    Article  PubMed  CAS  Google Scholar 

  41. Konopnicki D, Mocroft A, de Wit S, et al.: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:593–601.

    Article  PubMed  Google Scholar 

  42. Thio CL, Seaberg EC, Skolasky R Jr, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet 2002, 360:1921–1926.

    Article  PubMed  Google Scholar 

  43. Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678–686.

    Article  PubMed  Google Scholar 

  44. Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65–73.

    Article  PubMed  CAS  Google Scholar 

  45. Miailhes P, Trabaud MA, Pradat P, et al.: Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007, 45:624–632.

    Article  PubMed  Google Scholar 

  46. Puoti M, Cozzi-Lepri A, Paraninfo G, et al.: Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006, 11:567–574.

    PubMed  CAS  Google Scholar 

  47. Keeffe EB, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the united states: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315–1341.

    Article  PubMed  CAS  Google Scholar 

  48. Lo Re V 3rd, Frank I, Gross R, et al.: Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007, 44:315–320.

    Article  PubMed  Google Scholar 

  49. Gandhi RT, Wurcel A, Lee H, et al.: Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: Implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435–1441.

    Article  PubMed  CAS  Google Scholar 

  50. Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol 2008, 48:353–367.

    Article  PubMed  CAS  Google Scholar 

  51. Sulkowski MS: Management of hepatic complications in HIV-infected persons. J Infect Dis 2008, 197(Suppl 3):S279–S293.

    Article  PubMed  CAS  Google Scholar 

  52. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507–539.

    Article  PubMed  CAS  Google Scholar 

  53. Rockstroh JK, Bhagani S, Benhamou Y, et al.: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82–88.

    Article  PubMed  CAS  Google Scholar 

  54. McMahon MA, Jilek BL, Brennan TP, et al.: The HBV drug entecavir: effects on HIV-1 replication and resistance. N Engl J Med 2007, 356:2614–2621.

    Article  PubMed  CAS  Google Scholar 

  55. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008, 1–139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 2008.

  56. Benhamou Y, Fleury H, Trimoulet P, et al.: Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006, 43:548–555.

    Article  PubMed  CAS  Google Scholar 

  57. Sheldon J, Camino N, Rodes B, et al.: Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005, 10:727–734.

    PubMed  CAS  Google Scholar 

  58. Liaw YF, Gane E, Leung N, et al.: 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486–495.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine/Liver Diseases, Mount Sinai School of Medicine, One Gustave L. Levy Place, New-York, NY, 10029, USA

    Marie-Louise Vachon

Authors
  1. Marie-Louise Vachon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas T. Dieterich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marie-Louise Vachon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vachon, ML., Dieterich, D.T. HIV and coinfected patients. Curr hepatitis rep 8, 103–110 (2009). https://doi.org/10.1007/s11901-009-0015-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-009-0015-9

Keywords

Search

Navigation